Regardless of reaching a whole response with optimum induction therapy, minimal residual illness frequently persists, necessitating consolidation therapy to mitigate the risk of relapse by eliminating residual disease. In clients who have received 7+3 induction therapy, consolidation therapy is initiated with higher-dose cytarabine, often known as